Vascular Implant Surveillance and Interventional Outcomes Network (VISION)

2020 VISION: What we've done, and what lies ahead

Wednesday, September 2, 2020
9:30am - 2:30pm ET
Zoom Meeting:
https://weillcornell.zoom.us/j/98932134679

Chairs:

Philip Goodney, *Dartmouth-Hitchcock* & Art Sedrakyan, *Weill Cornell Medical Center*

Time	Topic	Presenter
9:00-9:15	**Sign-On**	
9:30-11:30	**AM Session: VISION Impact, Value and Sustainability**	
9:30 – 10:15	**VISION Impact from the Past Year** *Introduction and Goals (5 minutes)*	***Moderator*** Philip Goodney, MD, MS *Dartmouth-Hitchcock (VQI)*
	Gender Differences *(8 minutes)* *Commentary*: Danica Marinac-Dabic, MD, PhD, MMSc, FISPE, *FDA (4 minutes)*	***Speakers*** Niveditta Ramkumar, PhD, MPH *Dartmouth-Hitchcock*
	Long-Term Surveillance After EVAR *(8 minutes)* *Commentary:* Scott Williams, MS, RAC, *Cook (4 minutes)*	Jesse Columbo, MD, MS *Dartmouth-Hitchcock*
	VQI Center Specific Survival Reintervention and Surveillance (SRS) Reports (*8 minutes*) *Commentary*: Jens Eldrup-Jorgensen, MD, FACS, *Maine Health* (*4 minutes*)	Philip Goodney, MD, MS *Dartmouth-Hitchcock (VQI)*
10:15-10:45	**VISION Project Summaries from Investigators with Ongoing Projects**	***Moderator*** Philip Goodney, MD, MS *Dartmouth-Hitchcock (VQI)*
	Outcomes of Paciltaxel coated devices vs. non-drug coated devices *(7 minutes)* *Commentary:* Misti Malone, PhD, MS, *FDA*	***Speakers*** Daniel Bertges, MD *University of Vermont Medical Center*
	EVAR conversion events *(7 minutes)* *Commentary:* Brian Pullin, MS, *FDA;* Carmen Gacchina Johnson, PhD, *FDA (3 minutes)*	Salvatore Scali, MD, FACS, DFSVS, RPVI *University of Florida, Gainesville*

	Comparison of event calculation with and without claims-based follow-up *(7 minutes)* *Commentary*: Jacqueline Major, PhD, MS, *FDA (3 minutes)*	Livia de Guerre, MD *Beth Israel Deaconess*
10:45-11:30	**VISION Value-Driven Sustainability** *MDEpiNet Capabilities and Offerings (5 minute introduction by moderator)*	***Moderator*** Art Sedrakyan, MD, PhD *Weill-Cornell Medicine*
	Speakers	
	• Disparities in diffusion of endovascular devices: Goodney/Arya (*3 minute Quickshot presentation)*	Philip Goodney, MD, MS *Dartmouth-Hitchcock (VQI)*
	• Use of post-acute care and frailty: Arya/Goodney *(3 minute Quickshot presentation)*	Shipra Arya, MD, SM, FACS *Stanford*
	• Outcomes of dialysis access procedures: Woo *(3 minute Quickshot presentation)*	Karen Woo, MD *UCLA*
	• Using registry-claims linkages for randomized trial long-term follow up, including in VA populations: Farber *(3 minute Quickshot presentation)*	Alik Farber, MD *Boston Medical Center*
	• NOSI-120, COVID-19 Testing: Scali *(3 minute Quickshot presentation)*	Salvatore Scali, MD, FACS, DFSVS, RPVI *University of Florida, Gainesville*
	VISION and VQI: Potential Future Opportunities (*5 minutes*) *Commentary:* Greggory Pappas, MD, PhD, *FDA*	Jack Cronenwett, MD *Dartmouth Hitchcock (VQI)*
12:30-1:45	**PM Session: Afternoon Concurrent Breakout Sessions**	
	Breakout 1: Developing Technologic Solution and Future Directions for VISION	***Moderator*** Danica Marinac-Dabic, MD, PhD, MMSc, FISPE *FDA*
	Commentary:	***Commentary***
	• Integration with PROs: Tarver *(10 minutes)*	Michelle Tarver, MD, PhD *FDA*
	• Linkages to under-65 data: Columbo *(10 minutes)*	Jesse Columbo, MD, MS *Dartmouth-Hitchcock*
	• NESTcc Partnerships: Siami *(10 minutes)*	Sandi Siami, MPH *NESTcc*
	• Potential for expansion to other medical products (e.g. biologics): Cronenwett *(10 minutes)*	Jack Cronenwett, MD *Dartmouth-Hitchcock (VQI)*

Breakout 2: Operationalizing your Research Plan	***Moderator*** Andrew Hoel, MD *Northwestern Medicine*
Presentations • How do I work with VISION analytic team from start to finish: Moore/Mao *(20 minutes)*	***Speakers*** Kayla Moore, MPH *Dartmouth-Hitchcock* Jialin Mao, MD, MS *Weill Cornell Medicine*
• Prioritization of the research projects: Who goes first? Hoel (*10 minutes)*	Andrew Hoel, MD *Northwestern*
• Prioritization of research projects: What is FDA's perspective on this? Gacchina Johnson *(10 minutes)*	Carmen Gacchina Johnson, PhD *FDA*
Commentary and Q&A (20 minutes)	
Breakout 3: Regulatory Science, Stakeholders, and Policy	***Moderators*** Misti Malone, PhD, MS *FDA*
Commentary: • How to Leverage VISION for Maximum Impact: Implications for Industry: Malas *(10 minutes)*	***Commentary*** Mahmoud Malas, MD, MS *UCSD*
• What can Real World Evidence (RWE) be used for? Industry Perspective: Williams, Bloss, Scamperle, Simoes *(10 minutes)*	Scott Williams, MS, RAC, *Cook* Roberta Bloss, *Gore* Tiessa Simoes, *Medtronic* Keely Scamperle, *Gore*
• Expansion of RAPID analyses using VISION data (device evaluation): Bertges *(10 minutes)*	Daniel Bertges, MD *University of Vermont Medical Center*
• EDUCATE Summary: Goodney *(10 minutes)*	Philip Goodney, MD, MS *Dartmouth-Hitchcock (VQI)*
Discussion *(20 minutes)*	
Breakout 4: VISION Next Steps for Priority Areas in Disparities and Expansion of Indications	***Moderator*** Shipra Arya, MD, SM, FACS *Stanford*
Commentary: • The role of gender in device use: Arya *(10 minutes)*	***Commentary*** Shipra Arya, MD, SM, FACS *Stanford*
• Venous linkages and development: Osborne *(10 minutes)*	Nicholas Osborne, MD, MS *University of Michigan*

	• Veterans Affairs: opportunities for collaborations: Spangler, Mureebe *(10 minutes)*	Emily Spangler, MD *University of Alabama, Birmingham VA Medical Center* Leila Mureebe, MD, MPH *Duke, Durham VA Medical Center*
	• COVID collaboration: Wohlauer *(10 minutes)*	Max Wohlauer, MD, *University of Colorado*
	Discussion (20 minutes)	
2:00-2:30	**Report Back**	***Moderator*** Art Sedrakyan, MD, PhD *Weill-Cornell Medicine*
		Speakers
	• Breakout 1: Marinac-Dabic (*5 minutes)*	Danica Marinac-Dabic, MD, PhD, MMSc, FISPE *FDA*
	• Breakout 2: Hoel (*5 minutes)*	Andrew Hoel, MD *Northwestern Medicine*
	• Breakout 3: Malone (*5 minutes)*	Misti Malone, PhD, MS *FDA*
	• Breakout 4: Arya (*5 minutes)*	Shipra Arya, MD, SM, FACS *Stanford*
	Summary and next steps: Goodney/Sedrakyan *(10 minutes)*	

Please Note: All of the above times are in Eastern Daylight Time (EDT)